Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review
Jingqiu Li, Xiaoding Zhou, Lei Wu, Jiabao Ma, Yan Tan, Songke Wu, Jie Zhu, Qifeng Wang, Qiuling Shi
Springer Nature ·
2025-02-18
· DOI 10.1186/s12885-025-13712-0
The publisher did not provide an abstract — full text is available via the link below.
Jingqiu Li, Xiaoding Zhou, Lei Wu, Jiabao Ma, Yan Tan, Songke Wu et al. Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review. // BMC Cancer. – 2025. – DOI: 10.1186/s12885-025-13712-0. – URL: https://doi.org/10.1186/s12885-025-13712-0
Jingqiu Li, Xiaoding Zhou, Lei Wu, Jiabao Ma, Yan Tan, Songke Wu, Jie Zhu, Qifeng Wang, & Qiuling Shi (2025). Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review. BMC Cancer. https://doi.org/10.1186/s12885-025-13712-0
Jingqiu Li, et al. “Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review.” BMC Cancer, 2025. doi:10.1186/s12885-025-13712-0.
@article{Li2025,
title = {Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review},
author = {Li, Jingqiu and Zhou, Xiaoding and Wu, Lei and Ma, Jiabao and Tan, Yan and Wu, Songke and Zhu, Jie and Wang, Qifeng and Shi, Qiuling},
journal = {BMC Cancer},
year = {2025},
doi = {10.1186/s12885-025-13712-0},
url = {https://doi.org/10.1186/s12885-025-13712-0}
}